Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the ...

The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful ...

For the second time this week, a Big Pharma–partnered Parkinson’s disease asset has failed in the clinic. This time it’s ...

Dec. 23, 2024 — The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress ...

it can cause low blood pressure so is recommended only for patients for whom levodopa fails to prevent tremors. Dr Helmich is also investigating lifestyle changes that may reduce Parkinson's ...

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better ...

evaluated using a clinical measure called the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale [MDS-UPDRS].

The nominal p-value was 0.0431 in a prespecified analysis of the 75% of participants who also received the approved Parkinson ...

Prasinezumab missed statistical significance in delaying motor progression in early Parkinson's (HR=0.84, p=0.0657).

Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase I for Demyelinating Diseases.

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and commercialise monoclonal antibodies targeting α-syn, such as prasinezumab, ...

Genentech, a member of the Roche Group (RHHBY), announced that its phase IIb study of Prasinezumab in early-stage Parkinson's disease ...